# A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

> **NCT04479436** · PHASE2 · TERMINATED · sponsor: **Daiichi Sankyo** · enrollment: 40 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Patritumab Deruxtecan

## Key facts

- **NCT ID:** NCT04479436
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-14
- **Primary completion:** 2022-02-03
- **Final completion:** 2022-02-03
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Study was terminated early given the Interim Analysis for Part 1 (signal finding) did not meet pre-specified criteria and will not proceed to Part 2. Sponsor will proceed closing the study.
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04479436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04479436, "A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04479436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*